HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma

Tissue Antigens

Volumn 71, Issue 3, 2008, Pages 219-226

  Diepstra, A ^a   Poppema, S ^a   Boot, M ^a   Visser, L ^a   Nolte, I M ^a   Niens, M ^a   Te Meerman, G J ^a   Van Den Berg, A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Epstein Barr virus; Histocytochemistry; Hodgkin's disease; Human leukocyte antigens; Immune escape; Natural killer cells; Population genetics; Tumor

Indexed keywords

HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ADULT; AGED; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HISTIOCYTE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ALLELES; CHILD; FEMALE; GENETIC MARKERS; GENOTYPE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-A ANTIGENS; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; REED-STERNBERG CELLS;

HUMAN HERPESVIRUS 4;

EID: 38849095307     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2008.01005.x     Document Type: Article

References (63)

1. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med 1989 : 320 : 502 6.
2. Schwering I, Brauninger A, Klein U et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003 : 101 : 1505 12.
3. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002 : 21 : 4908 20.
4. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997 : 18 : 156 63.
5. Oudejans JJ, Jiwa NM, Kummer JA et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 1996 : 87 : 3844 51.
6. Dolcetti R, Frisan T, Sjoberg J et al. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. Cancer Res 1995 : 55 : 3675 81.
7. Frisan T, Sjoberg J, Dolcetti R et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995 : 86 : 1493 501.
8. Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 2001 : 61 : 6219 26.
9. Poppema S, Visser L. Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol 1994 : 145 : 37 41.
10. Lee SP, Constandinou CM, Thomas WA et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 1998 : 92 : 1020 30.
11. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998 : 92 : 2477 83.
12. Moretta L, Bottino C, Pende D, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: their origin, receptors and function. Eur J Immunol 2002 : 32 : 1205 11.
13. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, Bosch-Princep R, Reverter-Branchat G, Jaen-Martinez J, Pons-Ferre LE. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005 : 46 : 1581 91.
14. Konjevic G, Jurisic V, Banicevic B, Spuzic I. The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol 1999 : 104 : 144 51.
15. Jezewska E, Bjorkholm M, Giscombe R, Holm G, Tullgren O. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease. Clin Exp Immunol 1985 : 61 : 96 102.
16. Frydecka I, Kotlarek-Haus S, Kuliszkiewicz-Janus M, Kuliczkowski K. Natural killer (NK) activity in patients with Hodgkin's disease before, during and after multiple-agent therapy. Arch Immunol Ther Exp (Warsz) 1990 : 38 : 407 14.
17. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci U S A 1997 : 94 : 5249 54.
18. Le Gal FA, Riteau B, Sedlik C et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol 1999 : 11 : 1351 6.
19. Lindaman A, Dowden A, Zavazava N. Soluble HLA-G molecules induce apoptosis in natural killer cells. Am J Reprod Immunol 2006 : 56 : 68 76.
20. Paul P, Rouas-Freiss N, Moreau P et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol 2000 : 61 : 1177 95.
21. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A 1997 : 94 : 11520 5.
22. King A, Gardner L, Loke YW. Human decidual leukocytes do not proliferate in response to either extravillous trophoblast or allogeneic peripheral blood lymphocytes. J Reprod Immunol 1996 : 30 : 67 74.
23. Le Bouteiller P, Pizzato N, Barakonyi A, Solier C. HLA-G, pre-eclampsia, immunity and vascular events. J Reprod Immunol 2003 : 59 : 219 34.
24. Shiroishi M, Tsumoto K, Amano K et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003 : 100 : 8856 61.
25. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998 : 160 : 4951 60.
26. Llano M, Lee N, Navarro F et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998 : 28 : 2854 63.
27. Moretta L, Romagnani C, Pietra G, Moretta A, Mingari MC. NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol 2003 : 24 : 136 43.
28. Cantoni C, Falco M, Pessino A, Moretta A, Moretta L, Biassoni R. P49, a putative HLA-G1 specific inhibitory NK receptor belonging to the immunoglobulin superfamily. J Reprod Immunol 1999 : 43 : 157 65.
29. Paul P, Cabestre FA, Ibrahim EC et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 2000 : 61 : 1138 49.
30. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci U S A 2004 : 101 : 7064 9.
31. Le Rond S, Azema C, Krawice-Radanne I et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol 2006 : 176 : 3266 76.
32. Marshall NA, Christie LE, Munro LR et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004 : 103 : 1755 62.
33. Poppema S. Regulatory T cells in Hodgkin lymphoma. Blood 2004 : 103 : 1565 6.
34. Paul P, Rouas-Freiss N, Khalil-Daher I et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998 : 95 : 4510 5.
35. Urosevic M, Kurrer MO, Kamarashev J et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001 : 159 : 817 24.
36. Wiendl H, Mitsdoerffer M, Hofmeister V et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002 : 168 : 4772 80.
37. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003 : 13 : 371 7.
38. Urosevic M, Willers J, Mueller B, Kempf W, Burg G, Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002 : 99 : 609 17.
39. Amiot L, Onno M, Drenou B, Monvoisin C, Fauchet R. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum Immunol 1998 : 59 : 524 8.
40. Amiot L, Le Friec G, Sebti Y et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 2003 : 13 : 379 85.
41. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005 : 105 : 1694 8.
42. Sebti Y, Le Friec G, Pangault C et al. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol 2003 : 64 : 1093 101.
43. Gros F, Sebti Y, de Guibert S et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 2006 : 8 : 223 30.
44. Diepstra A, Niens M, Te Meerman GJ, Poppema S, van den Berg A. Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region. Eur J Haematol 2005 : 66 (Suppl 34 41.
45. Diepstra A, Niens M, Vellenga E et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet 2005 : 365 : 2216 24.
46. Menier C, Saez B, Horejsi V et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol 2003 : 64 : 315 26.
47. Lodererova A, Honsova E, Viklicky O. Detection of HLA-G on human extravillous cytotrophoblast and skeletal muscle with a new monoclonal antibody MEM-G/1. Folia Microbiol (Praha) 2003 : 48 : 239 42.
48. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986 : 137 : 2299 306.
49. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990 : 2 : 113 25.
50. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 1998 : 35 : 177 88.
51. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 2003 : 171 : 1918 26.
52. Cordell JL, Falini B, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984 : 32 : 219 29.
53. Maggio EM, Stekelenburg E, van den Berg A, Poppema S. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. Int J Cancer 2001 : 94 : 60 6.
54. Niens M, van den Berg A, Diepstra A et al. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev 2006 : 15 : 2280 4.
55. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol 1999 : 12 : 159 75.
56. van den Elsen PJ, Holling TM, Kuipers HF, van der SN. Transcriptional regulation of antigen presentation. Curr Opin Immunol 2004 : 16 : 67 75.
57. Niens M, Jarrett RF, Hepkema B et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 2007 : 110 : 3310 5.
58. Kikuchi-Maki A, Catina TL, Campbell KS. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein. J Immunol 2005 : 174 : 3859 63.
59. Rajagopalan S, Bryceson YT, Kuppusamy SP et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006. 4 : e9.
60. Roussev RG, Ng SC, Coulam CB. Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol 2007 : 57 : 262 9.
61. Herbst H, Foss HD, Samol J et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996 : 87 : 2918 29.
62. Gazit E, Sherf M, Balbin E, Muratov A, Goldstein I, Loewenthal R. HLA-G expression is induced in Epstein-Barr virus-transformed B-cell lines by culture conditions. Hum Immunol 2007 : 68 : 463 8.
63. Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol 2003 : 64 : 1057 63.